Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.

Optimisation of ADS100380, a sub-micromolar HDAC inhibitor identified using a virtual screening approach, led to a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids (6a-i), that possessed significant HDAC inhibitory activity. Subsequent functionalisation of the pendent phenyl group of compounds 6f and 6g provided analogues 6j-w with further enhanced enzyme and anti-proliferative activity. Compound 6j demonstrated efficacy in a mouse xenograft experiment.

[1]  P. Atadja,et al.  N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). , 2003, Journal of medicinal chemistry.

[2]  Takayoshi Suzuki,et al.  Non-hydroxamate histone deacetylase inhibitors. , 2005, Current medicinal chemistry.

[3]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[4]  Vigushin Dm,et al.  Histone deacetylase inhibitors in cancer treatment. , 2002 .

[5]  Takayoshi Suzuki,et al.  Rational design of non-hydroxamate histone deacetylase inhibitors. , 2006, Mini reviews in medicinal chemistry.

[6]  P. Finn,et al.  Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. , 2003, Molecular cancer therapeutics.

[7]  S. Grant,et al.  Histone deacetylase inhibitors in clinical development , 2004, Expert opinion on investigational drugs.

[8]  Thomas A. Miller.  Patent status of histone deacetylase inhibitors , 2004 .

[9]  H. W. Lee,et al.  Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. , 2000, Cancer research.

[10]  S. Remiszewski.  The discovery of NVP-LAQ824: from concept to clinic. , 2003, Current medicinal chemistry.

[11]  R A Rifkind,et al.  Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. , 2000, Cancer research.

[12]  H. Weinmann,et al.  Histone deacetylase inhibitors: a survey of recent patents , 2005 .

[13]  P. Marks,et al.  Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors , 1999, Nature.

[14]  N. L. La Thangue,et al.  Chromatin control and cancer-drug discovery: realizing the promise. , 2006, Drug discovery today.